UCLA Health

uclahealth.org

For more than half a century, UCLA Health has provided the best in healthcare and the latest in medical technology to the people of Los Angeles and throughout the world. Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center Santa Monica, Resnick Neuropsychiatric Hospital at UCLA, UCLA Mattel Children's Hospital, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health is among the most comprehensive and advanced healthcare systems in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NCCN ONCOLOGY RESEARCH PROGRAM AND PUMA BIOTECHNOLOGY, INC. COLLABORATE TO RESEARCH ON NERATINIB IN VARIOUS CANCERS

National Comprehensive Cancer Network | October 16, 2020

news image

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a $2-million grant from Puma Biotechnology, Inc. Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of: ...

Read More

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

news image

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More

Medical

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

news image

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

news image

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More
news image

NCCN ONCOLOGY RESEARCH PROGRAM AND PUMA BIOTECHNOLOGY, INC. COLLABORATE TO RESEARCH ON NERATINIB IN VARIOUS CANCERS

National Comprehensive Cancer Network | October 16, 2020

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a $2-million grant from Puma Biotechnology, Inc. Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of: ...

Read More
news image

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More
news image

Medical

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More
news image

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us